ointment (0.1%) to be more effective than UV treatment alone in patients with vitiligo.
ointment (0.1%) to be more effective than UV treatment alone in patients with vitiligo. [1] However, NB-UVB was administered for a minimum of 3 months and probably, more patients in the NB-UVB alone arm would have achieved better pigmentation, if phototherapy was given for a longer duration. Other studies with smaller sample size have found better pigmentation in NB-UVB and tacrolimus arm although the difference was not statistically significant. [2, 3] In our study 28% of patients had > 75% repigmentation. This is in contrast to the previous studies where higher pigmentation rate was achieved. [4, 5] This can be attributed to the fact that in our study 50% of the lesions were at resistant sites, where as in the previous studies the proportions of lesions at resistant sites were less, [4] or such sites were excluded from the analysis. [3, 5] Grade of repigmentation was strictly dependent on the site with lesions over face, trunk and limbs showing better outcome. Similar results were obtained in the study by Fai et al. [4] The limitations of the study include lack of blinding, use of subjective method in evaluating the extent of repigmentation and small sample size. The lack of statistical significance of difference in repigmentation in our study may be because of the smaller sample size and low power to detect all but large differences, and once daily use of tacrolimus rather than twice daily as currently recommended. Use of tacrolimus is expensive, cumbersome for the patients to apply over large vitiliginous areas and has photo-carcinogenic potential. As the additive effect of topical tacrolimus in combination with NB-UVB has not been fully established, long term prospective studies with larger sample size are required to conclusively establish the role of tacrolimus as an adjunct to NB-UVB in management of vitiligo.
Primary dapsone resistant Mycobacterium leprae in a non endemic country
Sir, Dapsone monotherapy in leprosy resulted in high resistance rates since the 1960s. After introduction of multidrug therapy (MDT), the rate declined but dapsone resistant Mycobacterium leprae has not been eradicated. [1] [2] [3] [4] [5] Leprosy is not endemic in Malaysia, however, surveillance of drug resistance was continued to guide therapy to prevent the spread of resistant strains. We report a 12 years surveillance of primary dapsone resistance using the mouse foot pad (MFP) technique.
Skin biopsy samples of multibacillary leprosy patients throughout the country were sent to the National Public Health Laboratory, Sungai Buloh. The MFP cultivation technique: Saline albumin is added to grounded 4 mm × 12 mm skin specimen containing lesion to produce a 10 4 bacilli/0.03 ml suspension. The suspension is inoculated into mice foot pads. The mice were given feeds mixed with dapsone concentrations of 0.01% or 0.001% or 0.0001%. Six mice were fed with each concentration. A control group of six mice was not treated. Reassessment of the inoculated M. leprae was performed by harvesting the footpad of one mouse from each group after six months, the rest of the mice were assessed after 12 months incubation. Our results showed a high prevalence of low level resistance, however, this is not associated with clinical therapy failure as the dose used in the MFP is equivalent to treating a patient with dapsone 1mg daily, compared to the standard dose of 100 mg daily. [1, 2] Intermediate and high level resistances are clinically significant.
There are a few reported prevalence of primary dapsone resistant M. leprae from this region. Kai et al., [3] in Vietnam found 6.1% folP1 mutation 33 new cases of leprosy and 6.4% in recently diagnosed cases between 2004 and 2009. In Yangoon, Myanmar between 2003 and 2005, there were 7.3% folP1 mutation in 54 new/ recent cases. [2] In Cebu Philippines (2001-2006), 2.6% folP1 mutation was seen in 77 new/recent cases. [2] Between 2000-2005, 0.8% folP1 mutation was reported in Indonesia (North Maluku, North Sulawesi). [2] Cambau et al., [1] in 1987-2000, found 14.3% folP1 mutation and equal number of resistance using the MFP in 21 new/recent cases in patients from the West Indies, Africa, Asia, and the Pacifics. In the 1980s, de la Cruz et al., [4] detected 21% dapsone resistance using the MFP in 38 new cases in Cebu, Philippines.
Our figures within the same period are higher compared to other countries. Although, in general, the prevalence is much lower compared to pre-MDT, dapsone resistance persisted. Current dapsone resistant M. leprae in Malaysia is likely acquired from patients with resistant strains in the pre-MDT era. Transmission of dapsone resistant M. leprae among close contacts has been demonstrated by Li et al., [5] in a molecular epidemiological study. Irregular therapy, inadequate coverage, and delay in diagnosis or treatment are other reasons why resistance continues.
M. leprae cultivation using MFP is currently the standard in drug susceptibility testing. However, the MFP is time consuming, labor intensive, and insensitive. Detection of mutation in the folP1 gene identifies dapsone resistance more rapidly, but compared to DNA methods, MFP differentiates viable and non-viable M. leprae and it reflects clinical efficacy. [1] Primary dapsone-resistance in Malaysia may increase further. Early identification of resistance using rapid methods of detection will help maintain the effectiveness of the MDT and prevent spread of resistant cases. M. leprae cultivation using MFP may be used in adjunct to molecular techniques.
